Tara Haelle June 09, 2021 Patients overwhelmingly found telemedicine care for headache a satisfactory and beneficial experience during the COVID-19 pandemic, according to a study presented at the American Headache Society’s 2021 annual meeting. Most patients who used telemedicine said they would like to continue using it after the pandemic, though the study also revealed barriers to care...
Tag: <span>headache</span>
Post
Does the Location of a Headache Matter?
By Osman Shabir, M.Sc.Reviewed by Dr. Jennifer Logan, MD, MPH Headaches can occur due to a variety of reasons, with most of them not being serious. Whilst there are well over 200 types of headache, there are typically two major types of headaches: primary (90%), in which the headache is a ‘headache-condition’ in itself (for example, migraine...
Post
Relivion Headset for Migraines Cleared in Europe
“I believe that the Relivion device from Neurolief has great potential to improve acute migraine therapy,” said Alan Rapoport, M.D., clinical professor of neurology at The David Geffen School of Medicine at UCLA, past president of the International Headache Society (IHS), and the founder and director-emeritus of The New England Center for Headache. “Not only...
Post
New antibody treatment provides little relief for high-frequency migraine patients
OREGON HEALTH & SCIENCE UNIVERSITY An early assessment reveals that a newly approved drug to treat migraines does not seem effective among patients who suffer from high-frequency migraines. The findings will be presented this week during the 61st annual scientific meeting of the American Headache Society in Philadelphia. Clinicians at OHSU in Portland, Oregon, conducted...
Post
Galcanezumab can cut frequency of cluster headache attacks
Peter J. Goadsby, M.D., Ph.D., from King’s College London, and colleagues enrolled patients who had at least one attack every other day, a total of at least four attacks, or no more than eight attacks per day during a baseline assessment. Recruitment was halted before the planned sample size of 162 patients was reached because too few volunteers...
Post
FDA approves first drug to help tame cluster headaches
Episodic cluster headaches are “an extremely painful and often debilitating condition,” the FDA’s Dr. Eric Bastings noted in an agency news release. He’s deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. Cluster headaches occur in quick sequence, “often at the same time(s) of the day, for several weeks...
Post
FDA approves drug for treatment of travelers’ diarrhea
Travelers’ diarrhea affects an estimated 10 to 40 percent of travelers worldwide each year, according to an FDA press release. The highest-risk destinations are most of Asia, the Middle East, Africa, Mexico, and Central and South America. (HealthDay)—The U.S. Food and Drug Administration on Friday announced it has approved Aemcolo (rifamycin), an antibacterial drug indicated...
Post
The burden of the ‘suicide’ headache
They’re called suicide headaches because the pain is frequent and unbearable. Commonly known as cluster headaches, they can occur up to eight times a day. They start suddenly, last for up to three hours, and can be very painful. A bout of regular attacks, known as a cluster bout, can last weeks to months. Dr....
Post
New once-a-month drug offers hope to millions with severe migraines (and it will be available next week)
The injected medication Aimovig is due to be available within the next week Unlike other migraine drugs, it does not cause side effects like weight gain Side effects can be worse than migraines, with up to 86% stopping treatment A study participant went from 27 migraines a month to two since January Some are concerned Aimovig...